WEST CHESTER, Ohio, Aug. 25 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will present at the following investor conferences during September:

-- The Thomas Weisel Partners Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 3, 2008. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 10:55 a.m. Eastern time.

-- The UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City on Thursday, September 25, 2008. Mr. Drachman is scheduled to present at 8:30 a.m. Eastern time.

Both presentations will be available live and by replay for 30 days following the presentations at www.atricure.com/Investor_Relations .

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) system, including its Isolator Synergy(TM) ablation clamps, and AtriCure's multifunctional pen and Coolrail(TM) linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure's multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use.

    Contact:

    AtriCure, Inc.
    Julie A. Piton
    Vice President and Chief Financial Officer
    (513) 755-4561
    jpiton@atricure.com

SOURCE AtriCure, Inc.